Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Corbus Pharmaceuticals Holdings Inc CRBP

Healthcare Biotechnology
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRBP)

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

GlobeNewswire 1 day ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

GlobeNewswire April 2, 2024

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 12, 2024

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

GlobeNewswire March 6, 2024

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

GlobeNewswire February 28, 2024

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 6, 2024

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 2, 2024

Corbus Pharmaceuticals Announces Pricing of Public Offering

GlobeNewswire January 31, 2024

Corbus Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire January 30, 2024
View More News ››

Opinion & Analysis (NDAQ:CRBP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CRBP)

Corbus Pharmaceuticals to Present at the Oppenheimer 34th An

News; $CRBP Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNORWOOD, Mass., Feb. 06,...
whytestocks - February 6, 2024

Corbus Pharmaceuticals Announces Closing of $94.5 Million Pu

News; $CRBP Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of...
whytestocks - February 2, 2024

$16.5M Bet On This Healthcare Stock? Check Out These 4 Stock

BREAKING NEWS: $CRBP $16.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying | BenzingaAlthough U.S. stocks...
whytestocks - January 31, 2024

BUY BUY BUY BUY BUY

Bought friday at 16.97 sold 39.50
Nibinator - January 27, 2024

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is a Lea

NEWS: $CRBP Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is a Leading Gainer in 1/26 Morning TradingCorbus Pharmaceuticals...
whytestocks - January 26, 2024

Incredible Value. ENTG at about 25% of One Years Revenue

.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for...
Wrywisdom - August 10, 2022
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »